Drug name - Invega Hafyera

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters Apr, 2036

(13 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; reinitiation of schizophrenia treatment following a missed dose 4-9 months ago

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
1.092GM/3.5ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1.560GM/5ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
273MG/0.875ML (273MG/0.875ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
410MG/1.315ML (311.79MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
546MG/1.75ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
819MG/2.625ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.